EAACI 2023

The symposium “From past to present: What’s next for CSU?”, hosted at EAACI 2023 in Hamburg, was chaired by dermatologist Dr Clive Grattan, alongside GA²LEN UCARE experts, Professor Emek Kocatürk Göncü and Professor Dr Martin Metz. The symposium explores the trajectory of this complex condition, unravelling its past to understand its present, and forecast its future. Watch the full symposium now!

Session 1: Dr Clive Grattan – Welcome and introductions

Session 2: Dr Clive Grattan – Exploring the Past: Approaches to CSU Care

Session 3: Professor Emek Kocatürk Göncü - Current Guidelines in CSU Management

Session 4: Professor Dr. Martin Metz - What’s New in Management: Future of Personalised Medicine

Session 5: Q&A discussion with all faculty

After participating in this educational programme, you will be able to:

• Recognise the advancement in clinical practice for the management of CSU
• Identify the advances in classification of CSU according to current guidelines
• Distinguish the differences in treatment options available for personalised medicine

CSU symposium overview 

This live symposium provided insight into emerging approaches to improve the diagnosis and treatment of chronic spontaneous urticaria (CSU) alongside the current guidelines. You will discover the updates in managing CSU patients, identify the advances in classification of CSU and distinguish the differences in treatment options available for personalised medicine. During the live event, attendees were able to participate in a Q&A session and listen to a panel discussion in which the experts provided insights based on their own clinical experience.

Meet the faculty

Dr Clive Grattan

Dr Clive Grattan is a consultant dermatologist at Guy’s and St Thomas’ Hospitals, London, UK.

Disclosures: Dr Clive Grattan is in receipt of honoraria or consultation fees from Novartis, Sanofi, Celltrion, Argenx, and Blueprint.

Professor Emek Kocatürk

Emek Kocatürk is Professor at the Department of Dermatology, Koç University School of Medicine, Istanbul, Turkey.

Disclosures: Speaker and advisor for Novartis, Menarini, LaRoche Posey, Sanofi, Bayer.

Professor Dr. Martin Metz

Prof. Dr Martin Metz is a Professor of Dermatology at the Institute of Allergology at the Charité – Universitätsmedizin and Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Allergology and Immunology, Berlin, Germany.

Disclosures: Prof. Dr Martin Metz is in receipt of honoraria or consultation fees from Amgen, AstraZeneca, Argenx, Celidex Therapeutics, Escientpharma, Jasper Therapeutics, Novartis, Pharvaris, Sanofi-Aventis, ThirdHarmonicBio.

Listen to further insights from the expert faculty and their key take home messages in these follow-up videos to the EAACI 2023 symposium, ‘From past to present: what’s next for CSU?’

Join Dr Clive Grattan, the chair of the symposium, as he outlines the challenges that HCPs face when treating CSU patients, and how these obstacles can be overcome with particular strategies and resources. Take a look into the future as Dr Grattan shares his thoughts on what areas of research hold the most promise for improving patient outcomes.

Professor Emek Kocatürk Göncü takes a look back at her symposium session on the current guidelines for CSU management; providing us with key insights into the main recommendations from the EAACI guidelines and impact on clinical practice. Emek further discusses the guidelines in addressing advanced treatment options and how these guidelines can be implemented to improve patient outcomes.

Prof. Dr Martin Metz takes a deep-dive into his symposium session focusing on the future of CSU management and personalised medicine. Gain insight into the emerging approaches and technologies that Prof. Dr Martin Metz foresees playing a significant role in precision medicine and the challenges that need to be addressed for successful implementation into CSU management. The expert discusses how the tools of personalised medicine could be implemented and touches on the importance of collaborative efforts to drive the future of personalised medicine.